Northfield Laboratories Inc. (NFLD) Wrap Up:

Northfield Laboratories Inc. is a leader in developing a hemoglobin-based oxygen-carrying red blood cell substitute for the treatment of urgent, large volume blood loss in trauma and resultant surgical settings. The initial indication we are seeking for our product, PolyHeme®, is the early treatment of urgent, life-threatening blood loss following trauma when donated blood may not be immediately available. We believe that this indication addresses a critical unmet medical need, since some trauma patients bleed to death before they have access to blood. We believe that PolyHeme has the potential to improve survival in critically injured patients who have delayed access to blood and whose expected mortality without oxygen-carrying replacement would be considerably greater. In July 2006 we announced the completion of patient enrollment in our pivotal Phase III trial with PolyHeme.  ... More..."http://secfilings.nasdaq.com/edgar_conv_html%2f2007%2f08%2f14%2f0000950137-07-012373.html#FIS_BUSINESS"